These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 3510731)

  • 21. Treatment of brain metastases from lung cancer: chemotherapy.
    Schuette W
    Lung Cancer; 2004 Aug; 45 Suppl 2():S253-7. PubMed ID: 15552807
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Surgery and multimodal treatments in pancreatic cancer--a review on the basis of future multimodal treatment concepts.
    Link KH; Leder G; Formentini A; Fortnagel G; Kornmann M; Schatz M; Beger HG
    Gan To Kagaku Ryoho; 1999 Jan; 26(1):10-40. PubMed ID: 9987495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The treatment of non-small cell lung cancer: current perspectives and controversies, future directions.
    Bunn PA
    Semin Oncol; 1994 Jun; 21(3 Suppl 6):49-59. PubMed ID: 8052874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity.
    Frei E; Elias A; Wheeler C; Richardson P; Hryniuk W
    Clin Cancer Res; 1998 Sep; 4(9):2027-37. PubMed ID: 9748116
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Chronology of administration of cytotoxic drugs and combinations of chemotherapy with radiotherapy].
    Tubiana M
    Bull Cancer; 1984; 71(4):301-12. PubMed ID: 6093914
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New developments in chemotherapy for advanced non-small cell lung cancer.
    Raez LE; Lilenbaum R
    Curr Opin Oncol; 2006 Mar; 18(2):156-61. PubMed ID: 16462185
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate.
    Goldie JH; Coldman AJ
    Cancer Treat Rep; 1979; 63(11-12):1727-33. PubMed ID: 526911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The application of mathematical modelling to aspects of adjuvant chemotherapy scheduling.
    Gaffney EA
    J Math Biol; 2004 Apr; 48(4):375-422. PubMed ID: 15052504
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical aspects of drug resistance.
    Sobrero A; Bertino JR
    Cancer Surv; 1986; 5(1):93-107. PubMed ID: 3297314
    [No Abstract]   [Full Text] [Related]  

  • 30. Optimal policies of non-cross-resistant chemotherapy on Goldie and Coldman's cancer model.
    Chen JH; Kuo YH; Luh HP
    Math Biosci; 2013 Oct; 245(2):282-98. PubMed ID: 23927854
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Finding the tumor copycat. Therapy fails, patients don't.
    Ellis LM; Fidler IJ
    Nat Med; 2010 Sep; 16(9):974-5. PubMed ID: 20823880
    [No Abstract]   [Full Text] [Related]  

  • 32. The experimental basis for combination chemotherapy.
    van Putten LM
    Cancer Treat Rev; 1984 Mar; 11 Suppl A():19-23. PubMed ID: 6733718
    [No Abstract]   [Full Text] [Related]  

  • 33. Drug dosage intensity--a panel discussion.
    McGuire WL; Goldie J; Hryniuk W; Tormey DC
    Breast Cancer Res Treat; 1987; 9(2):87-100. PubMed ID: 3620720
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distinguishing rational from irrational applications of pharmacogenetic synergies from the bench to clinical trials.
    Hucl T; Gallmeier E; Kern SE
    Cell Cycle; 2007 Jun; 6(11):1336-41. PubMed ID: 17568192
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cancer chemotherapy. Progress and expectations, 1984.
    Chabner BA; Fine RL; Allegra CJ; Yeh GW; Curt GA
    Cancer; 1984 Dec; 54(11 Suppl):2599-608. PubMed ID: 6388809
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-intensity combination chemotherapy maximizes host survival time for tumors containing drug-resistant cells.
    Martin RB; Fisher ME; Minchin RF; Teo KL
    Math Biosci; 1992 Jul; 110(2):221-52. PubMed ID: 1498451
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Arguments supporting the concept of non-cross-resistant combinations of chemotherapy.
    Goldie JH
    Cancer Invest; 1994; 12(3):324-8. PubMed ID: 8187010
    [No Abstract]   [Full Text] [Related]  

  • 38. Antineoplastic admixtures.
    Slimowitz R
    Am J Hosp Pharm; 1991 May; 48(5):945-6. PubMed ID: 1853875
    [No Abstract]   [Full Text] [Related]  

  • 39. Optimal control analysis of a cancer chemotherapy problem.
    Swan GW
    IMA J Math Appl Med Biol; 1987; 4(2):171-84. PubMed ID: 3503092
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The resistance phenotype in the development and treatment of cancer.
    Laconi E; Pani P; Farber E
    Lancet Oncol; 2000 Dec; 1():235-41. PubMed ID: 11905641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.